))
Test Innovations in Personalized Medicine: Overcoming Challenges and Embracing Change
Manage episode 377513947 series 3396813
内容由Perry Dimas提供。所有播客内容（包括剧集、图形和播客描述）均由 Perry Dimas 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Using genomics or other biomarkers to improve health care is the essence of Personalized Medicine according to today’s guest, Dr. Bruce Quinn. Moving forward with novel diagnostic testing could prove challenging for a variety of reasons, one of them being a disruption to the overall healthcare industry. If one test could replace multiple, costly tests, then the ROI for certain payors goes down.
Join us as we also discuss:
- The other challenges facing new tests
- Where test identifiers are heading
- The indirect interest of insurance sales
Dr. Quinn is the Principal at Bruce Quinn Associates LLC and is an expert in Medicare policy for innovative technology. His initial career was as a full-time medical school faculty member. Armed with an MBA in 2001, he shifted to a career in strategy consulting. He served as a regional Medicare Part B medical director 2004-2008. He has worked for a global consulting firm, Accenture, as well as for two DC-based health policy firms.
Since 2016, he has been an independent consulting primarily focused on genomics and digital technologies. His services include product planning and reimbursement pathways for innovators, as well as due diligence investigations for investors. His website on health policy and new technology, “Discoveries in Health Policy,” has had over a million views, holds 2000 articles, and has hundreds of subscribers from industry, academia, and government. Dr. Quinn is based in Los Angeles.
—----
Stay connected with our host, Perry Dimas, here on LinkedIn!
23集单集
分享
